Interleukin-2 (IL-2) and 13-cis retinoic acid (RA) decrease vascular endothelial growth factor (VEGF) and prolong clinical benefit in patients with advanced solid tumors showing a partial response (PR) or stable disease (SD) to chemotherapy. J Clin Oncol 2005: 2, 27s (supplement).